Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + bevacizumab + gemcitabine
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Cetuximab + bevacizumab + gemcitabine is a combination regimen consisting of **cetuximab** (a monoclonal antibody targeting epidermal growth factor receptor [EGFR]), **bevacizumab** (a monoclonal antibody targeting vascular endothelial growth factor [VEGF]), and **gemcitabine** (a nucleoside analog chemotherapeutic agent). Cetuximab blocks EGFR-mediated signaling and proliferation; bevacizumab inhibits angiogenesis by blocking VEGF; gemcitabine acts as a cytotoxic agent by inhibiting DNA synthesis. This combination has been investigated in clinical trials for treatment of advanced and resected pancreatic carcinoma, as well as metastatic colorectal cancer, with studies indicating that dual EGFR/VEGF pathway inhibition, even when combined with gemcitabine, did not produce substantial efficacy over existing standards, but demonstrated manageable toxicity profiles[1][5][7].
- Other names
- cetuximab + bevacizumab + gemcitabine
02
Targets
Beyond the preview
Go deeper on cetuximab + bevacizumab + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + bevacizumab + gemcitabine.